Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.
暂无分享,去创建一个
A. Savic | P. Fenaux | E. Hellström-Lindberg | U. Germing | A. Symeonidis | L. Malcovati | D. Bowen | J. Čermák | M. Mittelman | R. Stauder | T. D. de Witte | K. Mądry | S. Langemeijer | G. Sanz | O. Beyne-Rauzy | L. Sanhes | E. Luño | N. Blijlevens | D. Haase | D. Culligan | Alex G Smith | A. Almeida | A. Guerci-Bresler | C. V. van Marrewijk | S. Burgstaller | A. Tatic | L. de Swart | Mette Skov-Holm | N. G. Šimec | Alex Smith
[1] A. Ganser,et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.
[2] P. Fenaux,et al. Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry , 2015, British journal of haematology.
[3] F. Solé,et al. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group , 2015, Haematologica.
[4] P. Campbell,et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.
[5] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[6] C. Bloomfield,et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[8] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Solé,et al. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. , 2011, Leukemia research.
[10] C. Steidl,et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. , 2005, Leukemia research.
[11] A. Cuneo,et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype , 2001, Leukemia.
[12] J. Bennett,et al. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.
[13] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.